RCS - Kromek Group PLC - Kromek detectors in new Spectrum Dynamics scanner

KromekAnnouncement

12/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230912:nRSL0811Ma&default-theme=true

RNS Number : 0811M  Kromek Group PLC  12 September 2023

12 September 2023

 

Kromek Group plc

("Kromek" or the "Group")

 

Kromek detectors used in Spectrum Dynamics' new SPECT/CT scanner

Next generation scanner sets new standards in energy range, sensitivity and
resolution

 

Kromek (AIM: KMK), a leading developer of radiation and bio-detection
technology solutions for the advanced imaging and CBRN detection segments, is
pleased to announce that one of its key customers, Spectrum Dynamics Medical
("Spectrum Dynamics"), has introduced the latest addition to its next
generation digital SPECT/CT imaging portfolio, the VERITON-CT 300, for higher
energy imaging, using Kromek's digital detectors.

 

Based on Spectrum Dynamics' digital SPECT/CT platform, the VERITON-CT 300
Series' detector technology provides the benefits of increased sensitivity and
throughput for Nuclear Medicine clinical applications capable of using imaging
utilising up to 300 keV high-energy isotopes. This allows for greater
procedure efficiency in most exam types, as well as simultaneous acquisition
of multi-energy peak isotopes commonly used in theranostic imaging
applications.

 

A SPECT scan (single-photon emission computed tomography) is the technique of
using nuclear medicine tomographic imaging techniques with gamma rays to
provide detailed 3D functional images of the body. The SPECT/CT scanner
combines the framework of the CT anatomic scan with the functional information
provided by nuclear medicine imaging (SPECT scan). The images from each scan
are then fused together providing highly accurate anatomical detail in 3D,
allowing medical specialists to more accurately pinpoint the exact location of
any abnormality.

 

Cadmium zinc telluride ("CZT") is transforming the detector technology used in
medical imaging, leading to significantly shortened exam scan times, lower
radiation dose to the patient, improved image quality and quantitative
accuracy without compromise.  Kromek's high-performance digital detectors,
combined with Spectrum's 360-degree, wide-bore SPECT/CT scanner and its
advanced image reconstruction algorithms, increase the energy range up to 300
keV to support the throughput demand of current and new emerging nuclear
medicine clinical applications that set a new standard in patient care.

 

The 300 Series digital detector technology sets new standards with a 2-4 times
improvement in energy range, system sensitivity, and energy resolution. These
improvements will further shorten the scan times associated with current
analogue or state-of-the-art digital technology. The VERITON-CT Series also
eliminates the need for collimator replacement further streamlining and
simplifying workflow for various procedure types.

 

Arnab Basu, CEO of Kromek Group, said: "We are delighted that our CZT
detectors have been integrated into Spectrum Dynamics' VERITON-CT 300 SPECT/CT
systems. This enables enhanced image quality and breakthrough clinical
capabilities in digital SPECT/CT. Spectrum Dynamics has long been at the
forefront of developing next-generation SPECT/CT scanners to deliver better
patient outcomes, and we are pleased to be part of this significant advance in
nuclear medical imaging technology. There is real commercial momentum in this
area, as companies continue to realise the significant benefits of CZT-based
SPECT/CT systems, which is driving widespread adoption. As the only commercial
independent global supplier of CZT, Kromek is well-placed to capitalise on
this large market opportunity."

 

Gilad Yoeli, CEO of Spectrum Dynamics, added: "Clinical users across the world
provide us with feedback on the Nuclear Medicine challenges they face.
Providing the technology to address such challenges is what drives us. The
increased sensitivity, improved energy resolution, and broader energy range of
Kromek's detector technology make it the right choice for our customers'
future imaging platforms. To better meet the current and future needs of SPECT
imaging, Spectrum offers a full line of scanners, the 200 the 400 and now the
300, this offering allows nuclear medicine departments to base their entire
scanner fleet on advanced digital detector technology."

 

Change of Name of Nominated Adviser and Broker

 

The Group also announces that its Nominated Adviser and Broker has changed its
name to Cavendish Capital Markets Limited following completion of its own
corporate merger.

 

 

For further information, please contact:

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Paul Farquhar, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Tim Redfern/Charlotte Sutcliffe - ECM

 Michael Johnson/Tamar Cranford-Smith - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury/Henry Gamble                              +44 (0)20 4582 3500

 

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect critical
infrastructure, events, personnel and urban environments from the threat of
'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKFLFFXKLZBBD